To provide context, Dr. Igor Efimov is part of a group of scientists that was awarded a high profile research grant by the Leducq foundation as part of their transatlantic network of excellence. The project description and information on the research group can be found on the Leducq Foundation web-site.
I had the opportunity last year (Oct 1-2, 2018) to present my research at the annual Rhythm conference held at the Amsterdam Medical Center (AMC) in Amsterdam, Netherlands. It was privilege and pleasure to do so.
I had the opportunity to interact with some of the giants in my field of research (cardiac electrophysiology). I also got valuable feedback on my research, which for me, was one of the primary objectives for the trip. Mission accomplished!
One of the privileges of doing cutting edge biomedical research is the opportunity to invent new technology or application that can quickly be translated in to a clinically available product for the benefit of all who may need it. I feel fortunate to have that opportunity working with Dr. Igor Efimov in his lab at George Washington University (GWU). As such, with the guidance from GWU technology commercialization office, we have filed for a US patent. On one side, patents guarantee the return of an inventor’s investment and profit and, on the other side, ensure availability — by patent disclosure — of the invention for the society when the patent terminates. As a scientist, I am more driven by the need to contribute to society, and less so to make a profit. Hopefully, this is the first step in that direction. More details about this technology can be found here
My co-authored research article titled – Critical Volume of Human Myocardium Necessary to Maintain Ventricular Fibrillation was published in the peer review journal – Circulation. Arrhythmia and Electrophysiology. The article is available in print, in the December 2018 issue of the journal.
Briefly, the manuscript documents evidence using donor human hearts that ventricular arrhythmias (e.g., ventricular fibrillation) is only sustained if the cardiac tissue volume exceeds the cardiac wavelength volume . The article can be accessed here
My co-authored research article titled – PFEIFER: Preprocessing Framework for Electrograms Intermittently Fiducialized from Experimental Recordings was published in the peer review journal – Open Source Software. The article is available in print, in the December 2018 issue of the journal.
Briefly, the manuscript documents a Preprocessing Framework for Electrograms Intermittently Fiducialized from Experimental Recordings (PFEIFER) in the form of a MATLAB Graphical User Interface designed to process bioelectric signals acquired from experiments The article can be accessed here
My co-authored editorial titled – Irreversible electroporation: Proceed with caution was accepted for published in the peer review journal – Heart Rhythm. The article is available in print, in the December 2018 issue of the journal.
Briefly, the editorial provides a brief commentary on the use of electroporation (a biological phenomenon characterized by disruption of lipid membrane and creation of nano pores in the cell membrane, resulting from the delivery of high-voltage electrical pulses, such as during defibrillation) as a tumor ablation technique. The editorial can be accessed here